

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

By Hand Delivery

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Brooks, et al.)	
)	
Serial No.:	09/081,522)	Group Art Unit: 1644
)	
Filed:	May 19, 1998)	Examiner: P. Gambel
)	
Title:	INHIBITION OF ANGIOGENESIS)	
	IN DISEASE STATES WITH AN)	Confirmation No. 1607
	ANTI- α v β 3 MONOCLONAL)	
	ANTIBODY (AS AMENDED))	Our Ref.: TSRI 419.0 Con 1

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 and § 1.97

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicant hereby directs the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant." A legible copy of the two attached references are being submitted herewith.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.


Since this Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action after the filing of a Request for Continued Examination under §1.114, the fee required to be filed with the accompanying Supplemental Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 19-0962. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

September 16, 2003

Date

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937
Enclosure


Emily Holmes, Reg. No. 40,652

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

TSRI 419.0 C1

APPLICATION NO

09/081,522

APPLICANT

Brooks et al.

FILING DATE

05/19/98

GROUP

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,766,591	6/16/98	Brooks et al.			
	A02						
	A03						
	A04						
	A05						
	A06						
	A07						
	A08						
	A09						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Gutheil, et al., "Targeted Antiangiogenic Therapy for Cancer Using vitaxin: A Humanized Monoclonal Antibody to the Integrin $\alpha_v\beta_3$ ", Clin.Cancer Research 6: 3056-3061 (2000).
	C02	
	C03	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

